During the Health System Executive Summit, Candy Tsourounis, PharmD, and Elise Wozniak, PharmD got candid about the barriers and financial risk surrounding this innovative therapy.
News|Articles|February 1, 2003
Atomoxetine: A nonstimulant therapeutic option for children and adults with attention-deficit hyperactivity disorder
Atomoxetine, a norepinephrine reuptake inhibitor, is the first nonstimulant agent approved for the treatment of ADHD (Strattera, Lilly). It has been approved for use in pediatric and adult patients. Atomoxetine improves ADHD symptom severity versus placebo, as evaluated by the ADHD Rating Scale (ADHD RS), and its efficacy appears comparable to immediate-release methylphenidate. Atomoxetine requires dosage titration and may be administered once or twice daily. Common side effects seen in both pediatric and adult patients include nausea, decreased appetite, and dizziness. Dosage adjustments are necessary for patients receiving atomoxetine and cytochrome P450 2D6 inhibitors. Based on average wholesale price (AWP), atomoxetine is more costly than existing ADHD therapies. Atomoxetine provides an alternative ADHD therapy for patients who may fail or cannot tolerate conventional treatments.
Advertisement
Advertisement
Related to this article
Foundational Pharmacy Strategies’ Christine Johnston on how rebate structures, pending legislation, and a stalled pipeline are reshaping — and threatening — the biosimilar market heading into 2027.
Rex Hoffman, M.D., MBA, says physician shortages and burnout are the most underestimated pressures on health system.
Rex Hoffman, M.D., MBA, of Providence Holy Cross walks through a CMO’s day in a hospital that often runs 85% to 100% full, from safety huddles to discharges.
On average, caregivers want to see their children with ADHD fall asleep 30 minutes faster, but the best sleep treatments average approximately 20 minutes, a new survey study found.
Research findings presented at CHEST meeting show COPD hospital readmission drops with discharge checklists and navigation. Other research suggests targeting readmission prevention efforts on patents discharged to post-acute facilities.
As the pharmacist pipeline tightens, leaders from UC Davis Health, UCSF Health, and Sutter Health say financial sustainability now depends as much on capacity as on cost.
GLP-1 use in adults 65 and older with MASLD was linked to a 45% lower risk of death, and a 28% lower risk of hepatic decompensation, a new Houston Methodist Research Institute study shows.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
GLP-1 therapy tied to lower mortality and liver decompensation in older adults with MASLD
2
Kaiser’s formulary chief makes his case for a ‘total value’ model on biologics | HSES 2026
3
Health-system pharmacy leaders are being asked to solve a margin problem and it is costing hospitals | HSES 2026
4
The GLP-1 access gap in type 2 diabetes isn’t coverage — it’s physician awareness | HSES 2026
5